The expansion cohorts include ER+/HER2 breast cancer patients in combination with fulvestrant post CDK4/6 inhibitor failure, triple negative breast cancer patients and an additional cohort in solid tumors.
The study evaluates asciminib – a novel investigational treatment specifically targeting the ABL myristoyl pocket (STAMP) – in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic
Under the terms of this agreement, Engitix and Takeda will collaborate in the confirmation and validation of targets and preclinical development of therapeutics in liver fibrosis using Engitix’s
AstraZeneca has initiated a phase 1 trial of a monoclonal antibody combination called AZD7442, which is being developed for the prevention and treatment of Covid-19. Dubbed as NCT04507256,
CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC. CONTESSA is comparing tesetaxel dosed orally at 27
The manufacturing of the AZD1222 vaccine candidate will be taken up at Catalent’s commercial gene therapy manufacturing plant in Harmans, Maryland. Catalent said that it will prepare the
The trial was conducted among untreated patients with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone. “While the
The US-based clinical-stage biopharmaceutical company had recently launched a phase 1 trial for SAB-185 in healthy volunteers to evaluate its safety. Apart from its potential treatment of Covid-19,
OrthoMab is a clinically validated platform that uses the most advanced computational and experimental protein engineering methods to create IgG-like bispecific antibodies from any two antibody sequences. By
This ongoing registrational study is investigating motixafortide (BL-8040) for the mobilization of hematopoietic stem cells (HSCs) for autologous transplantation in patients with multiple myeloma. If the primary endpoint
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.